• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Lexxel (enalapril maleate-felodipine ER)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Lexxel (enalapril maleate-felodipine ER)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Lexxel has been approved for the treatment of hypertension. Lexxel (enalapril maleate-felodipine ER), combines the complementary action of the most frequently prescribed angiotensin converting enzyme (ACE) inhibitor Vasotec (enalapril maleate) and the newer generation long-acting calcium channel blocker (CCB) Plendil (felodipine). Lexxel is expected to be available in pharmacies in March.

    Lexxel is a fixed-dose combination product containing 5 mg enalapril and 5 mg felodipine. The medication is indicated for the treatment of hypertension in patients who fail to achieve adequate control with either enalapril or felodipine monotherapy.

    Side Effects

    In general, treatment with Lexxel is well tolerated with any adverse events being mild and transient. The most frequently observed clinical adverse events occur with an incidence of one percent or greater include headache, peripheral edema and dizziness. As with other combination medications containing ACE inhibitor component, Lexxel should be discontinues as soon as pregnancy is detected.

    Additional Information

    Hypertension is commonly treated with a variety of individual therapies. Of those treated, one out of two patients are prescribed either an ACE inhibitor or a CCB. When ACE inhibitor or CCB monotherapy falls, physicians often prescribe a combination of the two.

    Often referred to as the silent killer, hypertension affects 50 million Americans and is responsible for more than 40,000 deaths annually, according to the American Heart Association. Uncontrolled hypertension has been linked to stroke, heart attack and heart failure. Although the cause of 90-95 percent of cases of hypertension is unknown, the disease can be easily detected and controlled with medication. Despite available treatments, recent public health surveys suggest that only about one in five Americans with hypertension have their blood pressure adequately controlled.

    Approval Date: 1997-01-01
    Company Name: Astra Merck
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • TechInnovation-360x240.png

      Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

    • AskTheExperts-360x240.png

      Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing